ArticleCancer biology & therapy2019
Investigation of copper-cysteamine nanoparticles as a new photosensitizer for anti-hepatocellular carcinoma.
Article in Cancer biology & therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Copper-cysteamine nanoparticles in cancer treatment: a systematic review.Cell biology and toxicology · 2025Pooled it
- Cuproptosis and Disulfidptosis Converge to Empower PD-L1 Checkpoint Therapy via Cadict-Induced PD-L1 Translation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- A ROS-responsive core-shell microneedle platform integrating sonodynamic gas antibacterial therapy and modulating immunity for diabetic wound healing.Journal of nanobiotechnology · 2026Article
- Polyherbal-Mediated Synthesis of Copper Nanoparticles UsingJournal of functional biomaterials · 2026Article
- Cu-Cy Nps@ZIF-8@HA-Mediated Photodynamic Therapy for Cutaneous Squamous Cell Carcinoma.International journal of nanomedicine · 2026Article
- Microwave dynamic therapy induces ferroptosis in colorectal cancer by targeting PTK2B to regulate STAT3-mediated GPX4 expression.Molecular biomedicine · 2025Article
- Phototherapy in cancer treatment: strategies and challenges.Signal transduction and targeted therapy · 2025Review
- Ultraviolet (UV) radiation: a double-edged sword in cancer development and therapy.Molecular biomedicine · 2024Review
- Prospects of nanoparticle-based radioenhancement for radiotherapy.Materials horizons · 2023Review
- Advancements in the Application of the Fenton Reaction in the Cancer Microenvironment.Pharmaceutics · 2023Review
- Cu-doped TiOJournal of nanobiotechnology · 2023Article
- Copper metabolism and hepatocellular carcinoma: current insights.Frontiers in oncology · 2023Review
- An Overview of the Importance of Transition-Metal Nanoparticles in Cancer Research.International journal of molecular sciences · 2022Review
- Colorectal liver metastasis: molecular mechanism and interventional therapy.Signal transduction and targeted therapy · 2022Review
- Study of copper-cysteamine based X-ray induced photodynamic therapy and its effects on cancer cell proliferation and migration in a clinical mimic setting.Bioactive materials · 2022Article
- Photodynamic therapy: A next alternative treatment strategy for hepatocellular carcinoma?World journal of gastrointestinal surgery · 2021Article
- Recent Advances of Upconversion Nanomaterials in the Biological Field.Nanomaterials (Basel, Switzerland) · 2021Review
- Effects of Nanoparticle Size and Radiation Energy on Copper-Cysteamine Nanoparticles for X-ray Induced Photodynamic Therapy.Nanomaterials (Basel, Switzerland) · 2020Article
- A powerful combination of copper-cysteamine nanoparticles with potassium iodide for bacterial destruction.Materials science & engineering. C, Materials for biological applications · 2020Article
- Application of photodynamic therapy for liver malignancies.Journal of gastrointestinal oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. HCC is now the third leading cause of cancer deaths worldwide, with over 500,000 people affected. However, there is no complete effective (ideal) treatment for liver cancer yet, and the new methods are expected to be discovered. Herein, for the first time, we report the anti-HCC effects of copper-cysteamine nanoparticles (Cu-Cy NPs), a new type of photosensitizers. An in vitro 3-(4,5-dimethylthiazol- 2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay shows that Cu-Cy NPs could significantly reduce the activity of HepG2 cells at a very low dose after a short time of ultraviolet radiation. In addition, we found that cell death was induced by Cu-Cy NPs, which is associated with cellular apoptosis. This implied that apoptosis might be the main mechanism of the Cu-Cy's anti-HCC activity. Furthermore, we found that Cu-Cy NPs obviously inhibited the tumor growth in vivo. More interestingly, we found that the soluble Cu-Cy NPs were able to enter exosomes which were secreted by tumor cells, and exosomes could be used to deliver Cu-Cy NPs to target tumor cells. All these observations suggest that Cu-Cy NPs have a good potential for cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.